NCT07537088

Efficacy and Safety of Triple Therapy With Dulaglutide, SGLT2 Inhibitors, and Finerenone in Chinese Adults With Type 2 Diabetes and Chronic Kidney Disease

Efficacy and Safety of Dulaglutide, SGLT-2 Inhibitors, and Finerenone Triple Therapy in Chinese Adults With Type 2 Diabetes and Chronic Kidney Disease: A Multicenter, Prospective, Randomized Controlled Study

• Status: Not Yet Recruiting
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 468 (estimated)
• Sponsor: First Affiliated Hospital of Wannan Medical College · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate whether adding dulaglutide to the combination therapy of SGLT2i and finerenone can provide additional kidney protection and safety for Chinese adults with T2DM and CKD. Eligible participants will be adults with T2DM and mild-to-moderate CKD who have been receiving SGLT2 inhibitor plus finerenone for at least 3 months on the basis of maximum tolerated dose of renin-angiotensin system inhibitor (RASi). Participants will be randomly assigned to either continue the original regimen or to receive add-on therapy with dulaglutide.The study will last for 26 weeks, with participants required to attend scheduled visits for efficacy and safety assessments at Week 13 (±1 week) and Week 26 (±1 week, final visit).

Conditions

• T2DM
• CKD - Chronic Kidney Disease

Interventions

Type	Name	Description
DRUG	Dulaglutide	Dulaglutide 1.5 mg, once weekly
DRUG	SGLT2i	administered according to prescribing information
DRUG	Finerenone	administered according to prescribing information

Timeline

• Start date: 2026-05-01
• Primary completion: 2027-04-01
• Completion: 2027-07-01
• First posted: 2026-04-17
• Last updated: 2026-04-17